Monitoring Xylazine and Fentanyl Co-Detection Through Urine Drug Testing Amidst Evolving Substance Availability

1

Xylazine, a nonopioid veterinary sedative, has been present in the illicit drug supply for over a decade, primarily as an adulterant in the US Northeast.
2

Sugarman et al found that only 16.91% of fentanyl-positive urine drug tests also tested positive for xylazine, indicating a lower prevalence than previously reported.
3

Monthly xylazine concentrations peaked in 2023 but subsequently declined, while copositivity with fentanyl increased, especially in Western US regions.
4

Xylazine co-occurrence with fentanyl poses challenges for clinical treatment, as it causes prolonged sedation and requires specialized wound management.
5

The study highlights the need for expanded urine drug testing panels to include xylazine, as awareness of its presence in the drug supply remains limited.

1